BACKGROUND: The association between race and outcome of treatment for childhood acute myeloid leukemia (AML) has not been adequately studied. PROCEDURE: We compared the clinical characteristics, biological features, and outcomes between white and black children with AML who were treated on five consecutive clinical protocols (1980-2002) at St. Jude Children's Research Hospital. We used proportional hazards modeling to investigate the relation between race and outcome. RESULTS: We observed no statistically significant differences between the 229 white and 58 black patients in clinical characteristics, FAB subtype, cytogenetic features, or outcome. There were no significant differences in event-free survival (EFS) or overall survival (OS) between the two race groups in individual clinical trials or in all studies combined. For the study group as a whole, the 5-year survival estimate was 39.2% +/- 3.6% for white patients and 33.8% +/- 6.5% for black patients. However, on our most recent trial (AML-97), there was a trend towards inferior outcome among black patients: the 5-year survival estimates were 55.6% +/- 12.3% and 27.3% +/- 13.5% for whites and blacks, respectively. CONCLUSIONS: Although we detected no differences in treatment outcome between white and black children with AML over the entire study period, black children appear to have worse outcomes than white children during more recent studies. Improved treatment is needed for all children with AML. (c) 2006 Wiley-Liss, Inc.
BACKGROUND: The association between race and outcome of treatment for childhood acute myeloid leukemia (AML) has not been adequately studied. PROCEDURE: We compared the clinical characteristics, biological features, and outcomes between white and black children with AML who were treated on five consecutive clinical protocols (1980-2002) at St. Jude Children's Research Hospital. We used proportional hazards modeling to investigate the relation between race and outcome. RESULTS: We observed no statistically significant differences between the 229 white and 58 black patients in clinical characteristics, FAB subtype, cytogenetic features, or outcome. There were no significant differences in event-free survival (EFS) or overall survival (OS) between the two race groups in individual clinical trials or in all studies combined. For the study group as a whole, the 5-year survival estimate was 39.2% +/- 3.6% for white patients and 33.8% +/- 6.5% for black patients. However, on our most recent trial (AML-97), there was a trend towards inferior outcome among black patients: the 5-year survival estimates were 55.6% +/- 12.3% and 27.3% +/- 13.5% for whites and blacks, respectively. CONCLUSIONS: Although we detected no differences in treatment outcome between white and black children with AML over the entire study period, black children appear to have worse outcomes than white children during more recent studies. Improved treatment is needed for all children with AML. (c) 2006 Wiley-Liss, Inc.
Authors: Lorenzo Falchi; Michael J Keating; Xuemei Wang; Catherine C Coombs; Mark C Lanasa; Sara Strom; William G Wierda; Alessandra Ferrajoli Journal: Cancer Date: 2013-07-08 Impact factor: 6.860
Authors: Marko Kavcic; Brian T Fisher; Yimei Li; Alix E Seif; Kari Torp; Dana M Walker; Yuan-Shung Huang; Grace E Lee; Sarah K Tasian; Marijana Vujkovic; Rochelle Bagatell; Richard Aplenc Journal: Cancer Date: 2013-02-21 Impact factor: 6.860
Authors: Yimei Li; Joanna G Newton; Kelly D Getz; Yuan-Shung Huang; Alix E Seif; Brian T Fisher; Richard Aplenc; Lena E Winestone Journal: Pediatr Blood Cancer Date: 2018-12-26 Impact factor: 3.167
Authors: Lena E Winestone; Kelly D Getz; Tamara P Miller; Jennifer J Wilkes; Leah Sack; Yimei Li; Yuan-Shung Huang; Alix E Seif; Rochelle Bagatell; Brian T Fisher; Andrew J Epstein; Richard Aplenc Journal: Am J Hematol Date: 2016-12-07 Impact factor: 10.047
Authors: K Scott Baker; Stella M Davies; Navneet S Majhail; Anna Hassebroek; John P Klein; Karen K Ballen; Carolyn L Bigelow; Haydar A Frangoul; Cheryl L Hardy; Christopher Bredeson; Jason Dehn; Debra Friedman; Theresa Hahn; Gregory Hale; Hillard M Lazarus; C F LeMaistre; Fausto Loberiza; Dipnarine Maharaj; Philip McCarthy; Michelle Setterholm; Stephen Spellman; Michael Trigg; Richard T Maziarz; Galen Switzer; Stephanie J Lee; J Douglas Rizzo Journal: Biol Blood Marrow Transplant Date: 2009-09-25 Impact factor: 5.742
Authors: Christine M Hartford; Shiwei Duan; Shannon M Delaney; Shuangli Mi; Emily O Kistner; Jatinder K Lamba; R Stephanie Huang; M Eileen Dolan Journal: Blood Date: 2008-12-24 Impact factor: 22.113